Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SOLV Stock Forecast 2026-2027
$81.01
Current Price
$14.03B
Market Cap
Buy 7
Hold 5
Sell 3
Wall St Analyst Ratings
Distance to SOLV Price Targets
+23.4%
To High Target of $100.00
+4.9%
To Median Target of $85.00
-25.9%
To Low Target of $60.00
SOLV Price Momentum
+8.1%
1 Week Change
+14.1%
1 Month Change
+8.2%
1 Year Change
+2.2%
Year-to-Date Change
-8.2%
From 52W High of $88.20
+29.9%
From 52W Low of $62.38
📊 TOP ANALYST CALLS
Did SOLV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Solventum Corp is one of their latest high-conviction picks.
Latest SOLV Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, SOLV has a neutral consensus with a median price target of $85.00 (ranging from $60.00 to $100.00). The overall analyst rating is Buy (7.1/10). Currently trading at $81.01, the median forecast implies a 4.9% upside. This outlook is supported by 7 Buy, 5 Hold, and 3 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SOLV Analyst Ratings
7
Buy
5
Hold
3
Sell
SOLV Price Target Range
Low
$60.00
Average
$85.00
High
$100.00
Current: $81.01
Latest SOLV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SOLV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2026 | Wedbush | Michael Piccolo | Outperform | Initiates | $94.00 |
| May 6, 2026 | UBS | Neutral | Maintains | $N/A | |
| May 6, 2026 | Stifel | Buy | Maintains | $N/A | |
| May 6, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| May 6, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| May 6, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 27, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Apr 17, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Mar 24, 2026 | Rothschild & Co | Sell | Initiates | $N/A | |
| Feb 27, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Feb 27, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Feb 27, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Jan 26, 2026 | Keybanc | Overweight | Upgrade | $N/A | |
| Jan 20, 2026 | Mizuho | Outperform | Upgrade | $N/A | |
| Jan 7, 2026 | Stifel | Buy | Maintains | $N/A | |
| Dec 2, 2025 | BTIG | Buy | Upgrade | $N/A | |
| Nov 10, 2025 | UBS | Neutral | Maintains | $N/A | |
| Nov 7, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Oct 1, 2025 | UBS | Neutral | Initiates | $N/A | |
| Sep 15, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A |
Solventum Corporation (SOLV) Competitors
The following stocks are similar to Solventum Corp based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Solventum Corporation (SOLV) Financial Data
Solventum Corporation has a market capitalization of $14.03B with a P/E ratio of 9.9x. The company generates $8.26B in trailing twelve-month revenue with a 17.3% profit margin.
Revenue growth is -3.0% quarter-over-quarter, while maintaining an operating margin of +5.6% and return on equity of +34.8%.
Valuation Metrics
Market Cap
$14.03B
Enterprise Value
$18.76B
P/E Ratio
9.9x
PEG Ratio
-0.1x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
-3.0%
Gross Margin
+54.6%
Operating Margin
+5.6%
Net Margin
+17.3%
EPS Growth
-90.5%
Financial Health
Cash/Price Ratio
+4.0%
Current Ratio
1.1x
Debt/Equity
106.5x
ROE
+34.8%
ROA
+2.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Solventum Corporation (SOLV) Business Model
About Solventum Corporation
What They Do
Develops healthcare solutions using advanced technologies.
Business Model
The company generates revenue through three segments: MedSurg, which supplies various medical products; Dental Solutions, which offers dental and orthodontic products; and Health Information Systems, which provides software solutions for healthcare documentation and data management. By addressing diverse customer needs in the healthcare market, it builds a broad revenue base primarily in the U.S. and internationally.
Additional Information
Founded in 2023 and based in Eagan, Minnesota, Solventum Corporation focuses on leveraging material science, data science, and digital capabilities to innovate in healthcare. Its commitment to advancing medical technology positions it well within a growing industry.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
20,584
CEO
Mr. Bryan C. Hanson
Country
United States
IPO Year
2024
Website
www.solventum.comSolventum Corporation (SOLV) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 05, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Solventum Corporation (SOLV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
3 days ago
Quick Summary
Solventum Corporation (SOLV) presented at the Jefferies Global Healthcare Conference 2026, discussing its strategies and developments in the healthcare sector.
Why It Matters
Solventum Corporation's presentation at a major healthcare conference signals potential insights into growth, strategies, and innovations, influencing investor confidence and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Solventum (NYSE: SOLV) will participate in a fireside chat at the Jefferies Healthcare Conference on June 3, 2026, at 9:55 a.m.
Why It Matters
Management participation at a prominent healthcare conference can signal strategic insights and potential growth opportunities for Solventum, impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors in Medical Services stocks should consider Solventum (SOLV) and HealthEquity (HQY) for potential value. Analysis needed to determine which offers better value currently.
Why It Matters
The comparison of Solventum and HealthEquity indicates potential investment opportunities, highlighting which stock may provide better value and returns in the medical services sector.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Solventum Corporation (SOLV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
24 days ago
Quick Summary
Solventum Corporation (SOLV) presented at the Bank of America Global Healthcare Conference 2026, highlighting its strategic initiatives and future prospects in the healthcare sector.
Why It Matters
Solventum Corporation's presentation at a major healthcare conference highlights its strategic initiatives and potential growth, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Solventum (SOLV) has reached a significant support level and recently broke through its 200-day moving average, indicating a potential long-term bullish trend for investors.
Why It Matters
SOLV's breach of the 200-day moving average signals a potential long-term bullish trend, indicating favorable conditions for investment and possible price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
SOLV surpassed Q1 earnings and revenue expectations, driven by growth in MedSurg, Dental, and HIS sectors, despite facing sales declines and margin pressures.
Why It Matters
SOLV's Q1 earnings and revenue beat signals strong performance in key sectors, which may boost investor confidence and suggest resilience amid challenges.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About SOLV Stock
What is Solventum Corporation's (SOLV) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Solventum Corporation (SOLV) has a median price target of $85.00. The highest price target is $100.00 and the lowest is $60.00.
Is SOLV stock a good investment in 2026?
According to current analyst ratings, SOLV has 7 Buy ratings, 5 Hold ratings, and 3 Sell ratings. The stock is currently trading at $81.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SOLV stock?
Wall Street analysts predict SOLV stock could reach $85.00 in the next 12 months. This represents a 4.9% increase from the current price of $81.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Solventum Corporation's business model?
The company generates revenue through three segments: MedSurg, which supplies various medical products; Dental Solutions, which offers dental and orthodontic products; and Health Information Systems, which provides software solutions for healthcare documentation and data management. By addressing diverse customer needs in the healthcare market, it builds a broad revenue base primarily in the U.S. and internationally.
What is the highest forecasted price for SOLV Solventum Corporation?
The highest price target for SOLV is $100.00 from at , which represents a 23.4% increase from the current price of $81.01.
What is the lowest forecasted price for SOLV Solventum Corporation?
The lowest price target for SOLV is $60.00 from at , which represents a -25.9% decrease from the current price of $81.01.
What is the overall SOLV consensus from analysts for Solventum Corporation?
The overall analyst consensus for SOLV is neutral. Out of 2 Wall Street analysts, 7 rate it as Buy, 5 as Hold, and 3 as Sell, with a median price target of $85.00.
How accurate are SOLV stock price projections?
Stock price projections, including those for Solventum Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 11:51 AM UTC